Seeking Alpha

More on Zalicus (ZLCS +6.25%) Q2: company has again extended its partnership with Novartis...

More on Zalicus (ZLCS +6.25%) Q2: company has again extended its partnership with Novartis (NVS), "validating the value" of Zalicus' cHTS technology for developing cancer treatments. Zalicus is also on track to start Phase 2a trials of Z160, a drug for neuropathic pain, and to report results of a Phase IIb trial for Synavive, which is used for rheumatoid arthritis. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs